Trinity Biotech (TRIB) has released an update.
Trinity Biotech plc has announced the appointment of Louise Tallon as the new Chief Financial Officer, set to join in August 2024, succeeding interim CFO Des Fitzgerald. Tallon brings over 19 years of experience in the life sciences industry and is expected to drive the company’s transformation plan and the launch of a new continuous glucose monitoring device. The company maintains its financial goal of reaching $20 million in EBITDASO with $75 million in revenues by Q2 2025.
For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.
